Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


ICER And The VA: Match Made in Heaven?

Executive Summary

Institute for Clinical and Economic Review partners with the US Department of Veterans Affairs to support the agency's approach to negotiating and contracting for prescription drugs.

You may also be interested in...

Biogen/Eisai Will Explore Volume-Based Discounts For Aduhelm In Medicare

Deal with Veterans Administration also expected; companies say they will work with payers to ‘address’ pricing if patient population and uptake for their Alzheimer's drug are greater than expected.

Repatha Pricing Pressure Might Actually Increase After Outcomes Trial

Amgen's FOURIER study prompts ICER to plan new value-based price benchmark for Repatha below its previously recommended range of $5,404 to $7,735 per year.

Abuse-Deterrent Opioids: ICER Value Analysis Could Reinforce Coverage Restrictions

Draft report concludes that added cost of abuse-deterrent opioids is not outweighed by reductions to health care system costs resulting from their use.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts